Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRay trial of 177Lu-NeoB in GRPR-positive advanced solid tumors
NL-OMON58742Phase 2Completed
- Sponsor
- Advanced Accelerator Applications
- Start
- May 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of lutetium (177Lu) neobombesin in breast cancer, prostate cancer (PCa), gastrointestinal stromal tumor (GIST) and 3 more (6 arms), sponsored by Advanced Accelerator Applications. Started May 2022; status: completed.
02
Drugs
lutetium (177Lu) neobombesin
03
Conditions
breast cancerprostate cancer (PCa)gastrointestinal stromal tumor (GIST)glioblastoma (GBM)bronchial carcinoma
Beyond the preview
Go deeper on NL-OMON58742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58742.